JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, X.
Right arrow Articles by Schnellmann, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, X.
Right arrow Articles by Schnellmann, R. G.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ANTIMYCIN A
*CALCIUM COMPOUNDS
*CALCIUM, ELEMENTAL

Vol. 302, Issue 1, 88-94, July 2002

Cytoprotective Properties of Novel Nonpeptide Calpain Inhibitors in Renal Cells

Xiuli Liu, Jay F. Harriman1 and Rick G. Schnellmann2

Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, Arkansas

Calpains are cytosolic, Ca2+-activated, neutral cysteine proteases. Rabbit renal proximal tubule (RPT) cells express both µ- and m-calpain. Although multiple calpain inhibitors protect against RPT cell death, most calpain inhibitors lack specificity, membrane permeability, and/or potency. A group of novel catalytic site-directed calpain inhibitors, including chloroacetic acid N'-[6,7-dichloro-4-(4-methoxy-phenyl)-3-oxo-3,4-dihydroquinoxalin-2-yl]hydrazide (SJA7019) and chloroacetic acid N'-(6,7-dichloro-4-phenyl-3-oxo-3,4-dihydroquinoxalin-2-yl) hydrazide (SJA7029), were identified to be potent calpain inhibitors in vitro. The goals of this study were to determine the action of these two compounds on 1) RPT calpain activity using fluorescein isothiocyanate-casein zymography, 2) antimycin A-induced RPT extracellular 45Ca2+ influx and cell death, and 3) hypoxia/reoxygenation-induced RPT cellular dysfunction and death. The results showed that the SJA compounds inhibited RPT µ- and m-calpain with equal potency (approximate IC50, 30 µM) and efficacy, and blocked antimycin A-induced extracellular Ca2+ influx and cell death. In addition, SJA7029 blocked cell death and allowed the recovery of mitochondrial function and active Na+ transport in RPTs subjected to hypoxia/reoxygenation. In summary, the SJA compounds 1) were more potent inhibitors of calpains than catalytic site-directed peptide inhibitors in this model, 2) prevented extracellular Ca2+ influx during the late phase of cell death, and 3) are true cytoprotectants and allow recovery of RPT cellular functions after injury.


1 Current address: WIL Research Laboratories, Ashland, OH 44805.

2 Current address: Department of Pharmaceutical Sciences, Medical University of South Carolina, Charleston, SC 29425.


0022-3565/02/3021-0088$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
X. Liu and R. G. Schnellmann
Calpain Mediates Progressive Plasma Membrane Permeability and Proteolysis of Cytoskeleton-Associated Paxillin, Talin, and Vinculin during Renal Cell Death
J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 63 - 70.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.